LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

LTS Lohmann Therapie-Systeme AG is very pleased to announce the appointment of Mr. Bas van Buijtenen to the role of Chief Executive Officer effective 1 June 2020.

LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is pleased to announce the completion of the installation of solar panels atop of its warehouse building of its US affiliate, LTS Lohmann Therapy Systems, Corp.

Inspection successfully concluded. In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules.

10 year’s anniversary of LTS Wichtelgarten